What the FDA labels say about taking them together
Erlotinib and warfarin
Erlotinib's FDA label of June 10, 2024 names warfarin in its drug interactions section; the warfarin label PlainMeds reads does not name erlotinib. The erlotinib label: “The risk of MAHA is increased in patients with pancreatic cancer. Ocular disorders: Discontinue erlotinib for corneal perforation, ulceration or persistent severe keratitis. Hemorrhage in patients taking warfarin:”
Check it at the source: the erlotinib FDA label on DailyMed (effective June 10, 2024, Alembic Pharmaceuticals Limited); the warfarin FDA label on DailyMed (effective May 29, 2026, Amneal Pharmaceuticals LLC).
What does the erlotinib label say about warfarin?
Erlotinib label, drug interactionsAnticoagulants Interaction with coumarin-derived anticoagulants, including warfarin, leading to increased International Normalized Ratio (INR) and bleeding adverse reactions, which in some cases were fatal, have been reported in patients receiving erlotinib.
Erlotinib label, warnings and precautionsThe risk of MAHA is increased in patients with pancreatic cancer. (5.7) Ocular disorders: Discontinue erlotinib for corneal perforation, ulceration or persistent severe keratitis. (5.8) Hemorrhage in patients taking warfarin:
Source: FDA drug label (ERLOTINIB HYDROCHLORIDE), Alembic Pharmaceuticals Limited, effective June 10, 2024 (SPL set ab6f3cb3-34a8-4492-a5d7-fb6b055a2d6b), via openFDA; the full label on DailyMed
What does the warfarin label say about erlotinib?
Warfarin's label (effective May 29, 2026) does not name erlotinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Warfarin Sodium), Amneal Pharmaceuticals LLC, effective May 29, 2026 (SPL set 558b7a0d-5490-4c1b-802e-3ab3f1efe760), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Erlotinib | Warfarin | |
|---|---|---|
| Labeled for | Lung cancer | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.093 per tablet 2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once